Limits...
Type 2 diabetes mellitus and risk of malignant melanoma: a systematic review and meta-analysis of cohort studies.

Qi L, Qi X, Xiong H, Liu Q, Li J, Zhang Y, Ma X, Wu N, Liu Q, Feng L - Iran. J. Public Health (2014)

Bottom Line: The pooled relative risks with the corresponding 95% confidence intervals (95% CIs) were calculated by using random-effects or random-effects model.For the population-based studies in which case cohort established, the relative risk was 1.85 (95% CI, 1.31-2.62).Further studies are needed to specifically test the effect, and fully elucidate the underlying pathophysiologic mechanisms.

View Article: PubMed Central - PubMed

Affiliation: 1. Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China ; 2. Dept. of Military Epidemiology, Third Military Medical University, Chongqing, China.

ABSTRACT

Background: Epidemiology studies have demonstrated inconsistent associations between type 2 diabetes mellitus and the risk of malignant melanoma. To this end, the aim was to perform a meta-analysis of cohort studies.

Method: Medline, PubMed, Embase and the Cochrane Library were searched up to February 2014. Cohort studies addressing the relative risk of type 2 diabetes mellitus on malignant melanoma were included in this meta-analysis. The Newcastle-Ottawa Scale was applied for quality evaluation. The pooled relative risks with the corresponding 95% confidence intervals (95% CIs) were calculated by using random-effects or random-effects model. Heterogeneity and publication bias were evaluated by I (2) and funnel plot analysis, respectively. Data was analyzed using STATA 11.0.

Results: A total of 9 independent cohorts from 8 manuscripts were entered this meta-analysis. Type 2 diabetes mellitus was slightly associated with an increased risk of malignant melanoma, and the pooled relative risk was 1.15 (95% CI, 1.00-1.32) in diabetes compared with non-diabetes with significant evidence of heterogeneity among these studies (P=0.016, I (2) =57.6%). For the studies adjusted for age, gender and obesity, the relative risks were 1.21 (95% CI, 1.03-1.42), 1.17 (95% CI, 1.01-1.35) and 1.11 (95% CI, 1.00-1.24), respectively. For the population-based studies in which case cohort established, the relative risk was 1.85 (95% CI, 1.31-2.62).

Conclusion: Type 2 diabetes might be an independent risk factor for malignant melanoma. Further studies are needed to specifically test the effect, and fully elucidate the underlying pathophysiologic mechanisms.

No MeSH data available.


Related in: MedlinePlus

Analysis of studies were examined the association between T2DM and melanoma. RRs and 95% CI for all studies and the overall effect estimate are reported in the log scale. Among diabetics, the overall RR for melanoma is statistically significant at 1.15 (95% CI, 1.00-1.32)
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4401051&req=5

Figure 2: Analysis of studies were examined the association between T2DM and melanoma. RRs and 95% CI for all studies and the overall effect estimate are reported in the log scale. Among diabetics, the overall RR for melanoma is statistically significant at 1.15 (95% CI, 1.00-1.32)

Mentions: As shown in Fig. 2, the summary RR with 95% CI was 1.15 (95% CI, 1.00-1.32) in a random-effects model for individuals with T2DM compared with those without T2DM (Q =18.85, P=0.016, I2 =57.6%).


Type 2 diabetes mellitus and risk of malignant melanoma: a systematic review and meta-analysis of cohort studies.

Qi L, Qi X, Xiong H, Liu Q, Li J, Zhang Y, Ma X, Wu N, Liu Q, Feng L - Iran. J. Public Health (2014)

Analysis of studies were examined the association between T2DM and melanoma. RRs and 95% CI for all studies and the overall effect estimate are reported in the log scale. Among diabetics, the overall RR for melanoma is statistically significant at 1.15 (95% CI, 1.00-1.32)
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4401051&req=5

Figure 2: Analysis of studies were examined the association between T2DM and melanoma. RRs and 95% CI for all studies and the overall effect estimate are reported in the log scale. Among diabetics, the overall RR for melanoma is statistically significant at 1.15 (95% CI, 1.00-1.32)
Mentions: As shown in Fig. 2, the summary RR with 95% CI was 1.15 (95% CI, 1.00-1.32) in a random-effects model for individuals with T2DM compared with those without T2DM (Q =18.85, P=0.016, I2 =57.6%).

Bottom Line: The pooled relative risks with the corresponding 95% confidence intervals (95% CIs) were calculated by using random-effects or random-effects model.For the population-based studies in which case cohort established, the relative risk was 1.85 (95% CI, 1.31-2.62).Further studies are needed to specifically test the effect, and fully elucidate the underlying pathophysiologic mechanisms.

View Article: PubMed Central - PubMed

Affiliation: 1. Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China ; 2. Dept. of Military Epidemiology, Third Military Medical University, Chongqing, China.

ABSTRACT

Background: Epidemiology studies have demonstrated inconsistent associations between type 2 diabetes mellitus and the risk of malignant melanoma. To this end, the aim was to perform a meta-analysis of cohort studies.

Method: Medline, PubMed, Embase and the Cochrane Library were searched up to February 2014. Cohort studies addressing the relative risk of type 2 diabetes mellitus on malignant melanoma were included in this meta-analysis. The Newcastle-Ottawa Scale was applied for quality evaluation. The pooled relative risks with the corresponding 95% confidence intervals (95% CIs) were calculated by using random-effects or random-effects model. Heterogeneity and publication bias were evaluated by I (2) and funnel plot analysis, respectively. Data was analyzed using STATA 11.0.

Results: A total of 9 independent cohorts from 8 manuscripts were entered this meta-analysis. Type 2 diabetes mellitus was slightly associated with an increased risk of malignant melanoma, and the pooled relative risk was 1.15 (95% CI, 1.00-1.32) in diabetes compared with non-diabetes with significant evidence of heterogeneity among these studies (P=0.016, I (2) =57.6%). For the studies adjusted for age, gender and obesity, the relative risks were 1.21 (95% CI, 1.03-1.42), 1.17 (95% CI, 1.01-1.35) and 1.11 (95% CI, 1.00-1.24), respectively. For the population-based studies in which case cohort established, the relative risk was 1.85 (95% CI, 1.31-2.62).

Conclusion: Type 2 diabetes might be an independent risk factor for malignant melanoma. Further studies are needed to specifically test the effect, and fully elucidate the underlying pathophysiologic mechanisms.

No MeSH data available.


Related in: MedlinePlus